Uncategorized

Clinical Evaluation Reports (CER) & Post-Market Surveillance (PMS) Plans in MALTA

Published on October 13, 2026 By

Navigating the stringent landscape of medical device documentation requires technical rigor, data-driven synthesis, and uncompromised regulatory alignment. Water Chemicals Solution (Alkemist) provides industry-leading regulatory consultancy, delivering audit-ready Clinical Evaluation Reports (CER) and proactive Post-Market Surveillance (PMS) Plans tailored specifically for medical devices, borderlines, and device-associated chemical solutions entering or distributed within the Republic of Malta.

Applicable Regulations in MALTA

Medical device compliance in Malta is governed under the harmonized framework of the European Union, supervised locally by the Malta Medicines Authority (MMA). To achieve and maintain CE mark compliance, manufacturers and economic operators must comply with the following statutory instruments and guidance structures:

  • EU Medical Device Regulation (EU MDR 2017/745): Strict adherence to Annex XIV (Clinical Evaluation and Post-Market Clinical Follow-up) and Annex III (PMS Technical Documentation).
  • EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR 2017/746): Mandatory Performance Evaluation Reports (PER) and post-market performance monitoring.
  • Medicines Act (Cap. 458 of the Laws of Malta): National legislative framework governing clinical trials, medical devices, and pharmacovigilance interfaces.
  • Medical Device Coordination Group (MDCG) Guidelines: Direct integration of MDCG 2020-5, 2020-6 (clinical evaluation for legacy devices), MDCG 2020-7/8 (PMS and PSUR), and MDCG 2021-24.
  • MEDDEV 2.7/1 Rev. 4: Methodological baseline principles utilized in tandem with contemporary MDR expectations for systematic literature searching and clinical data appraisal.

What We Deliver for MALTA

Alkemist bridges high-level scientific evaluation with commercial viability. We support domestic Maltese manufacturers, European Authorized Representatives (EC REP), and international exporters by engineering robust clinical dossiers designed to pass Notified Body audits without frictional delays.

  • Audit-Proof Clinical Evaluation Reports (CER): Comprehensive state-of-the-art (SOTA) literature analysis, appraisal of clinical data, demonstration of equivalence, and quantifiable risk-benefit ratios aligned with MDR Annex XIV.
  • Proactive PMS Plans & Systems: Integrated PMS plans, Post-Market Clinical Follow-up (PMCF) strategies, Periodic Safety Update Reports (PSUR – Class IIa, IIb, III), and PMS Reports (Class I).
  • Fast Turnaround Times: Optimized data synthesis methodologies designed to meet rigid submission timelines, critical Notified Body corrective action deadlines, and tendering windows.
  • Localized Language Variants: Technical and user-facing documentation customized to Maltese statutory language requirements, including bilingual English and Maltese hazard communication, Instructions for Use (IFUs), and Summary of Safety and Clinical Performance (SSCP) documentation.
  • Export-Ready Files: Formatted, structured electronic technical dossiers configured for direct submission to the Malta Medicines Authority, Notified Bodies, and European centralized portals (EUDAMED).

Local Challenges We Solve

Malta’s geographical position as an island nation and critical Mediterranean logistics hub presents unique supply chain and administrative hurdles. Alkemist actively mitigates localized friction points to ensure uninterrupted market access:

  • Customs Delays & Port Clearance: Shipments entering via Malta Freeport or Luqa airfreight often face inter-agency border holds due to border classification disputes between medical devices, biocide washes, and industrial water chemical agents. We provide airtight regulatory boundary justifications that expedite clearance.
  • Hazard Phrasing Differences & Dual-Language Mandates: Divergence between standard EU CLP hazard phrases and localized device labeling expectations can trigger regulatory non-compliances. We ensure precise harmonization between device chemical components, Safety Data Sheets (SDS), and IFU risk phrasing.
  • EC REP & Economic Operator Due Diligence: Providing Maltese Authorized Representatives with fully defended clinical evidence to fulfill their statutory verification responsibilities under MDR Article 11 and Article 14.
  • Data Scarcity for Legacy Formulations: Resolving Notified Body challenges concerning historical clinical data for mature devices through robust SOTA benchmarking and structured equivalence validation.

Start Your Request

Ensure your medical device portfolios and associated specialty formulations maintain full market compliance across Malta and the European Union. Partner with the regulatory toxicologists, medical writers, and compliance engineers at Water Chemicals Solution (Alkemist).

To request a confidential dossier review, initiate a new Clinical Evaluation Report, or update your Post-Market Surveillance architecture, contact our compliance desk directly:

Email: admin@alkemist.org